Zacks Investment Research cut shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE) from a buy rating to a hold rating in a research report report published on Tuesday.
According to Zacks, “Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. “
Separately, Cowen and Company reaffirmed a buy rating on shares of Jounce Therapeutics in a research report on Friday, June 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Jounce Therapeutics has an average rating of Buy and a consensus target price of $23.67.
Jounce Therapeutics (JNCE) opened at 14.28 on Tuesday. The company’s 50-day moving average is $13.20 and its 200-day moving average is $19.40. Jounce Therapeutics has a 52-week low of $11.05 and a 52-week high of $29.29. The firm has a market capitalization of $458.87 million and a P/E ratio of 528.89.
Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $20.29 million for the quarter, compared to analyst estimates of $19.94 million. During the same period last year, the firm earned ($7.23) earnings per share. On average, analysts predict that Jounce Therapeutics will post ($0.62) EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new position in shares of Jounce Therapeutics during the first quarter worth $2,354,000. Laurion Capital Management LP acquired a new position in shares of Jounce Therapeutics during the first quarter worth $880,000. Omega Fund Management LLC acquired a new position in shares of Jounce Therapeutics during the first quarter worth $12,747,000. UBS Asset Management Americas Inc. acquired a new position in shares of Jounce Therapeutics during the first quarter worth $2,761,000. Finally, Wellington Management Group LLP acquired a new position in shares of Jounce Therapeutics during the first quarter worth $34,814,000. 40.83% of the stock is currently owned by hedge funds and other institutional investors.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.